Supernus Pharmaceuticals | SUPN - Ebitda


Supernus Pharmaceuticals reported $48.5M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Abbott USD 3.09B 44M Sep/2025
ANI Pharmaceuticals USD 65.36M 5.76M Dec/2025
Aurora Cannabis CAD 15.37M 26.8M Sep/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Canopy Growth CAD 16.62M 38.45M Sep/2025
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Corcept Therapeutics USD 4.2M 6.5M Dec/2025
Eisai JPY 30.1B 6.62B Dec/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Novo Nordisk DKK 37.3B 5.86B Dec/2025
Pacira USD 38.71M 10.65M Dec/2025
Perrigo USD 258.8M 37.3M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Supernus Pharmaceuticals USD 48.5M 6.6M Dec/2025
United Therapeutics USD 379.5M 83.4M Dec/2025
Xeris Pharmaceuticals USD 17.42M 8.83M Sep/2025